Parkinson Disease Clinical Trials 2023

What are the top hospitals conducting parkinson disease research?

When it comes to the pursuit of new treatments and breakthroughs for Parkinson's disease, several leading hospitals are at the forefront. In Nashville, Tennessee, Vanderbilt University Medical Center is making significant strides with five ongoing clinical trials focused on this debilitating condition. With a total of 26 trials conducted to date since their first recorded trial in 2007, Vanderbilt University Medical Center has established itself as a key player in Parkinson, Tennessee, Vanderbilt University Medical Center is making significant strides with five ongoing clinical trials focused on this debilitating condition. With a total of 26 trials conducted to date since their first recorded trial in 2007, Vanderbilt University Medical Center has established itself as a key player in Parkinson's research.

Meanwhile, the University of Florida in Gainesville has been actively pursuing solutions for Parkinson's disease as well. Currently engaged in four active clinical trials and having conducted 36 trials overall since their inaugural study in 2004, they have contributed significantly to advancing our understanding of this complex neurological disorder.

Another notable institution is the University of Alabama at Birmingham located in Birmingham. Like its counterpart in Gainesville, it too boasts four active clinical trials for Parkinson's disease and shares an equal tally of 36 completed studies thus far starting from their earliest recorded trial also dating back to 2004.

Stanford University joins this group with four ongoing clinical trials dedicated to investigating better treatment options for individuals living with Parkinson's disease. While having conducted ten previous studies related to this condition since initiating their first trial in 2008 makes them a formidable force within the field.

Lastly but not least,the Cleveland Clinic situated conveniently right within Cleveland; while conducting same number(4)of current running parkinson-disease-specific experiments similar like other peer institutions mentioned above but astonishingly surpasses all by holding thirty-eight past extensive investigations regarding parkinson diseasesince performing very first one way back during year two thousand six (which indeed puts them on top among participating members)

These esteemed medical centers serve as beacons of hope for patients battling Parkinson's disease worldwide. Through relentless dedication and innovative thinking exhibited by these hospitals' researchers,and physicians alike we can rest assured that every endeavor brings us closer towards finding effective treatments which shall surely make vast difference enhancing lives of millions suffering from this neurological condition.

Which are the best cities for parkinson disease clinical trials?

When it comes to Parkinson's disease clinical trials, several cities emerge as leaders in research and development. New York City boasts 13 active trials exploring treatments like LY3884961, Zoledronic acid (ZA), and ExAblate Pallidotomy. Philadelphia follows closely with 11 ongoing studies focused on interventions such as Gameficiation and Waitlist Couple Pairs Parkinson. New York City boasts 13 active trials exploring treatments like LY3884961, Zoledronic acid (ZA), and ExAblate Pallidotomy. Philadelphia follows closely with 11 ongoing studies focused on interventions such as Gameficiation and Waitlist Couple Pairs Parkinson's Group. Boston also offers 11 active trials examining options like mHealth delivered exercise programs and Digital music therapy. Chicago contributes to the field with 10 studies investigating treatments including Sulvecaltamide and Treadmill walking. Lastly, Miami is home to nine active trials that explore interventions such as Rock Steady Boxing classes and JM-010 combination Group B treatment. These cities provide individuals living with Parkinson's disease access to cutting-edge clinical trials that pave the way for advancements in care and improve quality of life.

Which are the top treatments for parkinson disease being explored in clinical trials?

Recent clinical trials have shed light on the top treatments being explored for Parkinson's disease. Among these potential game-changers is Felix, which has shown promise in one active trial dedicated to this neurodegenerative disorder. Additionally, Inspiratory Muscle Training has also caught researchers' attention with its positive results in a separate trial. Lastly, advanced treadmill walking has emerged as another avenue of exploration, showing encouraging outcomes in early studies. These breakthroughs offer hope for individuals living with Parkinson's disease and pave the way for improved management and treatment options moving forward.

What are the most recent clinical trials for parkinson disease?

Recent clinical trials for Parkinson's disease offer promising insights and potential breakthroughs in the field. One notable study is focused on eiDBS suppression, a Phase 4 trial that investigates the effectiveness of deep brain stimulation to alleviate symptoms associated with Parkinson's disease. Another trial, known as Waitlist Couple Pairs Parkinson's Group, explores innovative strategies to support individuals affected by this condition through group therapy sessions. Additionally, the i-BiSSkApp Group trial aims to evaluate the efficacy of a specific app in managing symptoms. The Delayed Start-PD study investigates whether delaying treatment initiation affects long-term outcomes for patients with Parkinson's disease. Lastly, IkT-148009 presently undergoes a Phase 2 trial to assess its potential therapeutic benefits in alleviating symptoms related to this neurodegenerative disorder.

What parkinson disease clinical trials were recently completed?

In the realm of Parkinson's disease research, numerous clinical trials have recently concluded, showcasing the commitment to finding effective treatments for this debilitating condition. Notably, Five Eleven Pharma completed a trial investigating [18F]P17-059 in July 2022. Additionally, AbbVie wrapped up their ABBV-951 trial along with BioVie Inc.'s NE3107 study in January 2022. These accomplishments are complemented by previous breakthroughs such as Michael J. Fox Foundation for Parkinson's Research concluding their [18F] PI-2620 trial in August 2021 and Eisai Inc.'s completion of the E2027 trial in February 2021. Each milestone brings hope closer for patients living with Parkinson's disease and highlights the tireless efforts made by researchers striving to improve their lives.